Results 51 to 60 of about 52,376 (272)
CAR‐Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune‐Mediated Inflammation
Advanced Science, EarlyView.CAR‐engineered cell therapies are expanding beyond cancer toward immune resetting, pathological‐cell clearance, matrix remodeling, and microenvironmental reprogramming in autoimmune, inflammatory, and fibrotic diseases. This Review compares CAR‐T, CAR‐macrophage, and CAR‐NK platforms and proposes controllable spatiotemporal reprogramming to align ...
Peng Jun Xu +6 more
wiley +1 more source
, 1991 The thesis is 72 publications describing the author's hypothesis of an autoimmune basis for myasthenia gravis (MG) and its validation. At the time of the first 24 papers many considered that MG was a syndrome rather than a disease entity, due to a ...
Simpson, John Alexander
core +3 more sources
MuSK (Muscle Specific Kinase) positive myasthenia: Grave prognosis or undue prejudice?
Annals of Indian Academy of Neurology, 2020 Objectives: Patients with muscle-specific kinase (MuSK)-positive myasthenia are generally considered to have a grave prognosis. We present our experience of patients with myasthenia with different antibody status. This is followed by a short discourse on
Priyanka Samal +3 more
doaj +1 more source
A Myasthenia Gravis Case Diagnosed Simultaneously with Diabetic Ketoacidosis [PDF]
, 2019 Juvenile myasthenia gravis (JMG) is an autoimmune disease caused by antibodies affecting the postsynaptic membrane at the neuromuscular junction. The association of JMG with Type I diabetes mellitus (DM), another autoimmune disease, is very rare and the ...
Zehra Aycan +4 more
core +1 more source
Clinical and therapeutic features of myasthenia gravis in adults based on age at onset [PDF]
, 2020 [Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).[Methods] This observational cross-sectional multicenter study was based on information in the neurologist-driven Spanish Registry of Neuromuscular ...
Sevilla, Teresa +33 more
core +1 more source
Interleukin‐39 is a Prognostic Biomarker and Therapy Target for Sepsis
Advanced Science, EarlyView.Sepsis triggers a significant increase in IL‐39 production, with circulating levels markedly elevated and positively correlated with disease severity and poor clinical prognosis in sepsis patients. Mechanistically, macrophage‐derived IL‐39 activates the GP130 signaling pathway via a ligand‐receptor interaction, thereby fueling the pro‐inflammatory ...
Feng‐zhi Zhang +9 more
wiley +1 more source
A case of successful treatment for epilepsy and myasthenia in a young female patient
Неврология, нейропсихиатрия, психосоматика, 2016 Epilepsy belongs to the diseases that show the high rate of comorbidity with another abnormality. The complexities of management of patients with two chronic diseases who need continuous treatment are related to the possible impact of therapy for one ...
T. V. Romanova, A. V. Yakunina
doaj +1 more source
Clinical and functional studies of autoimmune disorders of neuromuscular transmission [PDF]
, 2015 Inherited and acquired disorders of the neuromuscular junction are an important cause of muscle weakness and fatigability. In this thesis I focus on the autoimmune disorders of neuromuscular transmission.
Spillane, J
core
Myasthenia Gravis – a new era of treatment options [PDF]
Myasthenia Gravis is an autoimmune disease of the neuromuscular junction that causes fluctuating fatigable neuromuscular weakness. The spectrum of severity ranges from mild intermittent ptosis to respiratory failure requiring ventilatory support ...
Jennifer Spillane, Narmathey Thambirajah
core +1 more source
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial
Frontiers in Immunology, 2021 Patients diagnosed with malignancy, neurological and immunological disorders, i.e., fragile patients, have been excluded from COVID-19 vaccine trials.
Chiara Agrati +24 more
doaj +1 more source